Vertex Pharmaceuticals Inc

VRTX

NASDAQ. Currency in USD

320.76 +4.36 ( +1.38% )

Real time prices: December 01

Market Cap.
82.34B
Beta (5Y monthly)
0.43
Price/Earnings
21.80
EPS (TTM)
14.50
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.55M
1y Target Est.
324.62
Day's Range
315.18
-
321.52
52 Week's Range
202.00
-
323.61

Historical Summary

Performance
EPS growth
Share Buybacks

About Vertex Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.vrtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
254.25M
Employees
3900
Address
50 Northern Avenue, Boston, MA, United States, 02210
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest news

Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy...
By Zacks Investment Research - 2 days ago

2 Stocks Near 52-Week Highs That Could Climb Higher
2 Stocks Near 52-Week Highs That Could Climb Higher

This pair of stocks are bucking the trend and they could climb even higher.
By The Motley Fool - 3 days ago

Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead

The ARK Invest founder might regret trimming her position in this biotech stock.
By The Motley Fool - 6 days ago

BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory...
By Zacks Investment Research - 1 week ago

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease...
By Zacks Investment Research - 1 week ago

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved...
By Zacks Investment Research - 1 week ago

GSK to Withdraw Blenrep From U.S. Market on FDA Request
GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization...
By Zacks Investment Research - 1 week ago